Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TD-1473- Dose A · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Japanese subjects will receive oral doses of either TD-1473 - Dose A or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days. |
| Cohort 2 | EXPERIMENTAL | Japanese subjects will receive oral doses of either TD-1473 - Dose B or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days. |
| Cohort 3 | EXPERIMENTAL | Caucasian subjects will receive oral doses of either TD-1473 - Dose B or placebo (15 healthy Caucasian subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days. |
| Cohort 4 | EXPERIMENTAL | Japanese subjects will receive oral doses of either TD-1473 - Dose C or placebo (15 healthy Japanese subjects randomized 3:1 to 12 active and 3 placebo) once daily (QD) for 14 consecutive days. |
| Name | Type | Description |
|---|---|---|
| TD-1473 - Dose A | DRUG | oral capsule/tablet, QD |
| TD-1473 - Dose B | DRUG | oral capsule/tablet, QD |
| TD-1473 - Dose C | DRUG | oral capsule/tablet, QD |
| Placebo | DRUG | oral capsule/tablet, QD |
Inclusion Criteria: For All subjects: * Male or female between 18 to 55 years old * Female subjects must have documentation of a negative serum pregnancy test, * Female subjects must be either of non-childbearing potential or if of childbearing potential use a highly efficient birth control method...
TD-1473- Dose A is an investigational small molecule being developed for the treatment of Inflammatory Bowel Diseases (IBD). It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
TD-1473- Dose A is being developed by Theravance Biopharma, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol TBPH.
TD-1473- Dose A is in Phase 1 clinical development. It is an investigational drug and has not yet received regulatory approval for any use.
TD-1473- Dose A has one completed Phase 1 clinical trial, identified as NCT03750565, titled "Multiple Dose Ethnobridging PK Study in Healthy Subjects." This trial enrolled 60 participants in the United States and was a randomized, double-blind, controlled study.
TD-1473- Dose A is a specific dose formulation of the investigational drug TD-1473. The clinical trial NCT03750565 evaluates this particular dose in healthy subjects to assess its pharmacokinetic profile.